ProMACE-CytaBOM: Combination chemotherapy for diffuse large cell lymphoma

M. Prokocimer, M. Modan, S. Rusoshansky, O. Bairey, M. Shaklai

Research output: Contribution to journalArticlepeer-review

Abstract

ProMACE CytaBOM, a polychemotherapy regimen consisting of cyclophosphamide, doxorubicin, etoposide cytozar, bleomycin, vincristine, methotrexate and prednisone was administered on an outpatient basis to six consecutive patients with diffuse large cell lymphoma. All achieved a complete remission (CR). Two have relapsed. Actuarial analysis predicts 66.7% survival and 62.5% probability of remaining in remission at 40 months post diagnosis. The side effects of ProMACE CytoBOM were tolerable and included mainly vincristine induced peripheral neuropathy, infections and mucositis. Our results are consistent with the SWOG results, reported only recently, using the same combination chemotherapy regimen in patients with intermediate and high-grade non-Hodgkin's lymphomas. We conclude that ProMACE CytaBOM represents a highly effective and easy-to-administer regimen in patients with large cell lymphoma.

Original languageEnglish
Pages (from-to)1233-1236
Number of pages4
JournalAnticancer Research
Volume9
Issue number4
StatePublished - 1989
Externally publishedYes

Fingerprint

Dive into the research topics of 'ProMACE-CytaBOM: Combination chemotherapy for diffuse large cell lymphoma'. Together they form a unique fingerprint.

Cite this